Core 1: Planning and Evaluation

规划和评估核心（PEC）的目标是监测、评估和评估我们的 U 54在实现其里程碑、目标和目的方面的伙伴关系。核心支持我们的加州大学， 滨江（UCR）-希望之城综合癌症中心（CoHCCC）U 54伙伴关系的能力目标- 建筑、教育和培训。在这个U 54中，UCR和CoHCCC旨在发展合作， 翻译资源和培训计划，以提高癌症研究的多样性，并实现平等， 药物开发-贯穿整个药物开发管道。为了实现PEC的目标， 由四个委员会-内部咨询委员会（IAB），外部咨询委员会（EAB），社区咨询委员会 (CAB)多样性、公平和包容委员会（Diversity，Equity，and Inclusion Board，DEI）我们的IAB和EAB在指导我们的 P20规划补助金;在我们提议的U 54中，这两个委员会将由我们新创建的CAB和DEI加入。 这两个新董事会的加入强调了我们U 54对1）为不同个人服务的承诺 他们生活在南加州社区，2）指导和培训多样化的早期调查人员 他们致力于消除我们目前在癌症治疗、药物开发和获取方面的差距， 临床试验通过PEC的活动和监督，我们的四个咨询委员会将1）进行 评估、跟踪和报告项目和核心项目的进展情况; 2）提供重点反馈， U 54项目领导和调查人员。正如我们的P20规划赠款一样，U 54 PEC将与IAB合作， 提供一个结构化和严格的审查过程，以选择新的全面和试点项目以及小型试点项目， 能力核心。PEC将评估我们U 54伙伴关系的所有组成部分。PEC将确保 1)研究和评估核心培训和教育方案在提供教育和 能力建设，2）外展核心与调查人员合作，以包容我们所服务的社区，以及3） 能力核心识别为早期研究者（ESI）提供目标识别、药物 开发和临床试验。我们预计，我们的核心将共同发挥关键作用，在发展未来 U 54项目，建立UCR在药物开发和临床试验方面的能力。

The goals of the Planning and Evaluation Core (PEC) are to monitor, evaluate, and assess the progress of our U54 Partnerships in meeting its milestones, objectives, and goals. The Core supports our University of California, Riverside (UCR) – City of Hope Comprehensive Cancer Center (CoHCCC) U54 Partnership’s goals of capacity- building, education, and training. Together in this U54, UCR and CoHCCC aim to develop the collaborations, translational resources, and training programs to enhance diversity in cancer research and achieve equity in drug development - throughout the entire drug development pipeline. To achieve our PEC’s goals we are guided by four boards – the Internal Advisory Board (IAB), External Advisory Board (EAB), Community Advisory Board (CAB), and Diversity, Equity, and Inclusion Board (DEI). Our IAB and EAB have served a key role in guiding our P20 planning grant; in our proposed U54 these two boards will be joined by our newly created CAB and DEI. The inclusion of these two new boards underscores our U54’s commitment to 1) serving the diverse individuals that live in our Southern California communities and 2) to mentor and train a diverse early-stage investigators who are committed to eliminating our current disparities in cancer therapeutics, drug development, and access to clinical trials. Through the activities and oversight of the PEC, our four advisory boards will 1) conduct evaluation, tracking, and reporting of the progress of projects and cores and 2) provide focused feedback to program U54 leadership and investigators. As in our P20 planning grant, the U54 PEC will work with the IAB to provide a structured and rigorous review process to select new Full and Pilot projects as well as Mini-Pilots for the Capacity Core. The PEC will assess all components of our U54 partnership. The PEC will assure that the 1) Research and Evaluation Core training and education programs are effective in providing education and building capacity, 2) Outreach Core works with investigators to be inclusive of the communities we serve, and 3) Capacity Core identifies provides early-stage investigators (ESI) with mentorship in target identification, drug development, and clinical trials. We anticipate that together our Cores will play a key role in developing future U54 projects that build UCR’s capacity in drug development and clinical trials.